371,629 Shares in Bausch Health Cos Inc. $BHC Bought by Lido Advisors LLC

Posted by George Bondi on Jun 8th, 2026

Lido Advisors LLC acquired a new position in shares of Bausch Health Cos Inc. (NYSE:BHC – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 371,629 shares of the company’s stock, valued at approximately $2,583,000.

Several other institutional investors and hedge funds have also modified their holdings of BHC. Dynamic Technology Lab Private Ltd bought a new stake in shares of Bausch Health Cos during the 1st quarter worth $68,000. Jones Financial Companies Lllp lifted its position in shares of Bausch Health Cos by 1,548.9% during the 1st quarter. Jones Financial Companies Lllp now owns 24,965 shares of the company’s stock worth $162,000 after buying an additional 23,451 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Bausch Health Cos by 97.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 948,322 shares of the company’s stock worth $6,136,000 after buying an additional 467,270 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Bausch Health Cos by 3.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 324,847 shares of the company’s stock worth $2,102,000 after buying an additional 9,834 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Bausch Health Cos by 11.2% during the 2nd quarter. Geode Capital Management LLC now owns 840,418 shares of the company’s stock worth $5,597,000 after buying an additional 84,892 shares during the last quarter. 78.65% of the stock is currently owned by institutional investors.

Bausch Health Cos Price Performance

Bausch Health Cos stock opened at $5.38 on Monday. The company has a current ratio of 1.32, a quick ratio of 0.97 and a debt-to-equity ratio of 54.68. The company has a market capitalization of $2.01 billion, a PE ratio of -1.66 and a beta of 0.40. Bausch Health Cos Inc. has a 12 month low of $4.67 and a 12 month high of $8.69. The stock has a 50-day moving average price of $5.47 and a two-hundred day moving average price of $6.02.

Bausch Health Cos (NYSE:BHC – Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.03). The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.37 billion. Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. Analysts expect that Bausch Health Cos Inc. will post 4.08 EPS for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on BHC shares. Wall Street Zen downgraded Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Royal Bank Of Canada dropped their price objective on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research report on Monday, April 27th. Barclays dropped their price objective on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 25th. Finally, Weiss Ratings downgraded Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $8.00.

Check Out Our Latest Analysis on Bausch Health Cos

Insider Buying and Selling

In other Bausch Health Cos news, Director Frank D. Lee sold 24,456 shares of the stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total value of $132,796.08. Following the completion of the transaction, the director directly owned 49,339 shares in the company, valued at approximately $267,910.77. This trade represents a 33.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.67% of the company’s stock.

Bausch Health Cos Company Profile

(Free Report)

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.